iBio (IBIO) Current Deferred Revenue (2015 - 2026)

iBio (IBIO) has 11 years of Current Deferred Revenue data on file, last reported at $1.2 million in Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 91.67% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $1.2 million, a 91.67% increase from a year earlier, with the FY2025 full-year figure at $1.2 million, up 500.0% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $1.2 million, roughly flat from $1.2 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for IBIO reached as high as $1.2 million in Q2 2025 and fell as low as $8000.0 in Q1 2022.
• Historically, Current Deferred Revenue has averaged $537076.9 across 4 years, with a median of $400000.0 in 2024.
• Across the five-year window, Current Deferred Revenue sank 99.1% in 2022 and soared 500.0% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $88000.0 in 2022, then surged by 581.82% to $600000.0 in 2024, then jumped by 91.67% to $1.2 million in 2025, then changed by 0.0% to $1.2 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $1.2 million in Q1 2026, $1.2 million in Q4 2025, and $1.2 million in Q3 2025.